nivolumab
View Patient InformationA fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
Synonym: | nivolumab biosimilar ABP 206 nivolumab biosimilar BCD-263 nivolumab biosimilar CMAB819 |
---|---|
US brand name: | Opdivo |
Abbreviation: | NIVO |
Code name: | ABP 206 BMS-936558 CMAB819 MDX-1106 ONO-4538 |